Skip to main content
SpringerLink
Log in

How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?

  • Practice Point
  • Published:

From Nature Clinical Practice Gastroenterology & Hepatology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34 (Suppl 1): 12–18

    Article  CAS  Google Scholar 

  2. Targan SR et al. (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337: 1029–1035

    Article  CAS  Google Scholar 

  3. Sandborn W et al. (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984–1989

    Article  CAS  Google Scholar 

  4. Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285

    Article  CAS  Google Scholar 

  5. Anderson PJ (2005) Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34 (Suppl 1): 19–22

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. professor of gastroenterology at Imperial College London, Hammersmith Hospital, Du Cane Road, London, UK

    Subrata Ghosh

Authors
  1. Subrata Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Subrata Ghosh.

Ethics declarations

Competing interests

The author has declared associations with the following companies: Abbott, Schering Plough, Centocor and UCB.The author has been a member of the advisory board of Abbott, Schering Plough, Centocor and UCB. He has received honorarium for lecturing in conferences sponsored by Schering Plough and UCB. The author has also received funding from Schering Plough to support research.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghosh, S. How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease?. Nat Rev Gastroenterol Hepatol 3, 540–541 (2006). https://doi.org/10.1038/ncpgasthep0605

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0605

  • Springer Nature Limited

Search

Navigation